The recent discovery of the link between the human microbiome and a host of chronic disorders is
one of the most exciting scientific developments of this century. The discovery is so significant that
the World Economic Forum considers Human Microbiome Therapeutics (HMT) to be one of the top
10 emerging technologies in 2014 (World Economic Forum, 2014).
Freshwerkz, a Singapore biotech company, is a first mover in the area of HMT (see website).
The Company develops and markets HMT products which help to rebalance disrupted human gut microbiome and treat ailments such as type 2 diabetes, hyperlipidaemia, depression and anxiety, attention deficit hyperactivity disorder (ADHD), autism spectrum disorder, eczema, allergies, and cancer.
In February 2016, Dr Chia Boon Tat and Ms Lee Hwee Teng, founders of Freshwerkz Biotech based in Singapore, were wondering what they need to do to increase public awareness in order to boost sales of the three phytosynbiotics products developed and commercialised by the company.
Read the report here.